Literature DB >> 24035802

The ethics of placebo-controlled trials: methodological justifications.

Joseph Millum1, Christine Grady.   

Abstract

The use of placebo controls in clinical trials remains controversial. Ethical analysis and international ethical guidance permit the use of placebo controls in randomized trials when scientifically indicated in four cases: (1) when there is no proven effective treatment for the condition under study; (2) when withholding treatment poses negligible risks to participants; (3) when there are compelling methodological reasons for using placebo, and withholding treatment does not pose a risk of serious harm to participants; and, more controversially, (4) when there are compelling methodological reasons for using placebo, and the research is intended to develop interventions that can be implemented in the population from which trial participants are drawn, and the trial does not require participants to forgo treatment they would otherwise receive. The concept of methodological reasons is essential to assessing the ethics of placebo controls in these controversial last two cases. This article sets out key considerations relevant to considering whether methodological reasons for a placebo control are compelling.
© 2013.

Entities:  

Keywords:  Ethics; Placebo control; Randomized controlled trial

Mesh:

Substances:

Year:  2013        PMID: 24035802      PMCID: PMC3844122          DOI: 10.1016/j.cct.2013.09.003

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  26 in total

1.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.

Authors:  Iris Pigeot; Juliane Schäfer; Joachim Röhmel; Dieter Hauschke
Journal:  Stat Med       Date:  2003-03-30       Impact factor: 2.373

2.  Making "me-too" drugs benefit the public.

Authors:  Neil J Nusbaum
Journal:  Am J Med Qual       Date:  2002 Nov-Dec       Impact factor: 1.852

3.  The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs?

Authors:  David Wendler; Ezekiel J Emanuel; Reidar K Lie
Journal:  Am J Public Health       Date:  2004-06       Impact factor: 9.308

4.  The standard of care debate: the Declaration of Helsinki versus the international consensus opinion.

Authors:  R K Lie; E Emanuel; C Grady; D Wendler
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

5.  International ethical guidelines for biomedical research involving human subjects.

Authors: 
Journal:  Bull Med Ethics       Date:  2002-10

6.  What makes clinical research in developing countries ethical? The benchmarks of ethical research.

Authors:  Ezekiel J Emanuel; David Wendler; Jack Killen; Christine Grady
Journal:  J Infect Dis       Date:  2004-02-17       Impact factor: 5.226

7.  The ethics of clinical research in the Third World.

Authors:  M Angell
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

8.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues.

Authors:  R Temple; S S Ellenberg
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

9.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

10.  Single-injection or continuous femoral nerve block for total knee arthroplasty?

Authors:  Eric Albrecht; Dorothea Morfey; Vincent Chan; Rajiv Gandhi; Arkadiy Koshkin; Ki Jinn Chin; Sylvie Robinson; Philippe Frascarolo; Richard Brull
Journal:  Clin Orthop Relat Res       Date:  2014-05       Impact factor: 4.176

View more
  24 in total

Review 1.  Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis.

Authors:  Arnaud Leroy; Florian Naudet; Guillaume Vaiva; Andrew Francis; Pierre Thomas; Ali Amad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-21       Impact factor: 5.270

2.  Meaningful outcome research to validate endoscopic treatment of common lumbar pain generators with durability analysis.

Authors:  Kai-Uwe Lewandrowski; Anthony Yeung
Journal:  J Spine Surg       Date:  2020-01

3.  Should patients skip late doses of medication? A pharmacokinetic perspective.

Authors:  Elias D Clark; Sean D Lawley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-06-20       Impact factor: 2.410

4.  Red Blood Cell Transfusion at a Hemoglobin Threshold of 7 g/dl in Critically Ill Patients: A Regression Discontinuity Study.

Authors:  Nicholas A Bosch; Anica C Law; Jacob Bor; Laura C Myers; Nareg H Roubinian; Vincent X Liu; Allan J Walkey
Journal:  Ann Am Thorac Soc       Date:  2022-07

5.  Placebo-controlled clinical trials: how trial documents justify the use of randomisation and placebo.

Authors:  Tapani Keränen; Arja Halkoaho; Emmi Itkonen; Anna-Maija Pietilä
Journal:  BMC Med Ethics       Date:  2015-01-11       Impact factor: 2.652

6.  Ethical considerations in placebo-controlled randomised clinical trials.

Authors:  Kenneth R Kaufman
Journal:  BJPsych Open       Date:  2015-06-30

Review 7.  Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.

Authors:  Felipe Saldanha-Araujo; Emãnuella Melgaço Garcez; Amandda Evelin Silva-Carvalho; Juliana Lott Carvalho
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

8.  Virtual Reality-Based Cognitive Stimulation on People with Mild to Moderate Dementia due to Alzheimer's Disease: A Pilot Randomized Controlled Trial.

Authors:  Jorge Oliveira; Pedro Gamito; Teresa Souto; Rita Conde; Maria Ferreira; Tatiana Corotnean; Adriano Fernandes; Henrique Silva; Teresa Neto
Journal:  Int J Environ Res Public Health       Date:  2021-05-16       Impact factor: 3.390

9.  Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.

Authors:  F A Cadegiani; A Goren; C G Wambier; J McCoy
Journal:  New Microbes New Infect       Date:  2021-07-07

10.  Efficacy of an exercise intervention for employees with work-related fatigue: study protocol of a two-arm randomized controlled trial.

Authors:  Juriena D de Vries; Madelon L M van Hooff; Sabine A E Geurts; Michiel A J Kompier
Journal:  BMC Public Health       Date:  2015-11-12       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.